SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
New York, NY, Dec. 21, 2017 -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced the payment of a dividend for 2017. The Board of Directors has unanimously approved an annual dividend payment of $0.03 per share. This dividend will be paid on Friday, December 29, 2017 to Daxor shareholders of record on Thursday, December 21, 2017.
Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single-use diagnostic kit. For more information regarding blood volume analysis and the Daxor BVA-100, visit Daxor’s website at www.Daxor.com.
Daxor contact information: Michael Feldschuh, President and CEO. 212-330-8505 [email protected] John Wilkens, Chief Financial Officer. 212-330-8504 [email protected]
